Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Interim Trading Statement

19 Jul 2012 07:00

RNS Number : 9983H
Biome Technologies PLC
19 July 2012
 



19 July 2012

 

Biome Technologies plc ("Biome", "the Company" or "the Group")

 

Interim Trading Statement

 

 

Biome Technologies plc, the bioplastics and RF technology business, is pleased to announce a trading update, ahead of its Interim Results for the six-month period ended 30 June 2012, which are expected to be announced on 3 September 2012.

 

Total Group revenues achieved in the first half of 2012 were £7.5m, down 28% on the same period in 2011. In the Trading Update of 31 May, it was stated that sales within the Bioplastics Division for April and May were markedly below our expectations following legislative changes in Italy and wider disruption to the supply and demand balance in Europe. This is reflected in the second quarter, with Group revenues of £2.9m (Q2 2011: £4.9m), 38% below the revenues of £4.6m achieved in the first quarter.

 

The Bioplastics Division saw revenues drop from £4.3m in Q1 to £2.2m in the second quarter (Q2 2011: £3.9m). Within this, Biotec was most adversely affected with revenues down 58% from £3.0m in Q1 to £1.2m in the second quarter (Q2 2011: £1.8m) as third-party sales were depressed due to the previously reported demand changes in southern Europe. In Biome Bioplastics, revenues were down a more modest 26% to £1.0m in the second quarter compared to £1.3m in Q1 (Q2 2011: £2.2m) with some evidence that the broader application base and geographic diversity is providing greater resilience to the current turbulence in the market.

 

The Stanelco RF Technologies Division continues to perform as expected with revenues of £0.7m in Q2, up 95% compared to the first quarter (Q2 2011: £0.9m). The pipeline for fibre optic furnace systems and associated spares continues to grow; orders for nine units to the value of £1.2m have been received and are under build for the second half, with further orders pending. Diversification into new industrial markets continues and the Durapipe UK project is progressing well with the first prototype unit expected to be delivered shortly.

 

The Group's cash position at 30 June 2012 was £1.1m (30 April 2012: £1.5m). Following the period end, the Group announced that Biotec had entered into a €1.5m loan agreement with Sparkasse Emmerich and that €255k in repayment and interest had been repaid to Biome under the shareholder agreement. The Group's secured debt facility of up to £2m with Fortis Commercial Finance remains available but is currently not utilised.

 

The Board continues to believe that these market developments constitute a pause in a fast developing market and that the drivers of requirements for biodegradable and bio-based materials will grow with time.

 

With respect to the patent litigation, updated on 12 July, the recent positive findings in the Court of Turin in the context of other court findings provide further confidence in the value and potential of the Group's technology Biome is well placed and continues to expedite new product development with a focus on those opportunities likely to yield growth in the shorter term. Actions to reduce costs by around by £0.6m on an annualised basis have now been completed and the benefits will build in the second half. The Group is trading in-line with the Board's revised expectations.

 

-Ends-

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com Tel: +44 (0) 2380 867 100

 

Daniel Stewart & Company plc

David Hart/Jamie Barklem

www.danielstewart.co.uk Tel: +44 (0) 20 7776 6550

 

First Columbus

Chris Crawford/Kelly Gardiner

www.first-columbus.com Tel: +44 (0) 20 3002 2070

 

FTI Consulting

Oliver Winters/Latika Shah Tel: +44 (0) 20 7831 3113

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFWFWAFESEEW
Date   Source Headline
18th Apr 202310:49 amRNSCompletion of CLN Fundraising
17th Apr 202311:30 amRNSResult of General Meeting
31st Mar 202311:14 amRNSProposed issue of Convertible Loan Notes
25th Jan 20237:00 amRNSTrading Update
16th Nov 20227:00 amRNSBiome receives £282k grant
10th Nov 202211:05 amRNSSecond Price Monitoring Extn
10th Nov 202211:00 amRNSPrice Monitoring Extension
10th Nov 20227:00 amRNSTrading Update
18th Oct 20229:28 amRNSHolding(s) in Company
22nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:36 pmRNSPrice Monitoring Extension
22nd Sep 20222:05 pmRNSSecond Price Monitoring Extn
22nd Sep 20222:00 pmRNSPrice Monitoring Extension
22nd Sep 20229:05 amRNSSecond Price Monitoring Extn
22nd Sep 20229:00 amRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSInterim Results
5th Sep 20227:00 amRNSGrant funding from Innovate UK
2nd Aug 20228:59 amRNSTrading Update - Replacement
2nd Aug 20227:00 amRNSTrading Update
20th Apr 202212:01 pmRNSResult of Annual General Meeting
20th Apr 20227:00 amRNSTrading Update
30th Mar 20222:48 pmRNSDirector/PDMR Shareholding
30th Mar 20227:00 amRNSNotice of AGM and 2021 Annual Report
24th Mar 20227:00 amRNSFinal Results 2021
27th Jan 20227:00 amRNSTrading Update
4th Jan 202210:33 amRNSFurther substantial contract win for RF Division
16th Dec 20218:41 amRNSContract
17th Nov 20217:00 amRNSTrading Update
9th Nov 202111:12 amRNSHolding(s) in Company
25th Oct 20217:00 amRNSUpdate re biodegradable tree shelters
15th Sep 20217:00 amRNSInterim Results
30th Jul 20219:47 amRNSDirector/PDMR Shareholding
29th Jul 20217:00 amRNSTrading Update
1st Jul 20219:05 amRNSSecond Price Monitoring Extn
1st Jul 20219:00 amRNSPrice Monitoring Extension
1st Jul 20217:00 amRNSTrading Update
30th Jun 20215:00 pmRNSTotal Voting Rights
7th Jun 202110:50 amRNSHolding(s) in Company
2nd Jun 20217:00 amRNSIssue of Equity and TVR
28th May 20217:00 amRNSAward under 2017 Long Term Incentive Plan
30th Apr 20215:00 pmRNSTotal Voting Rights
27th Apr 20214:25 pmRNSHolding(s) in Company
21st Apr 202110:51 amRNSHolding(s) in Company
21st Apr 202110:19 amRNSResult of Annual General Meeting
21st Apr 20217:00 amRNSTrading Update
9th Apr 20211:40 pmRNSPDMR Shareholding and transaction in own shares
1st Apr 202110:04 amRNSIssue of equity and Transaction in own shares
29th Mar 20217:00 amRNSNotice of AGM and Annual Report
25th Mar 20217:01 amRNSFinal Results 2020
25th Mar 20217:00 amRNSAppointment of New Non-Executive Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.